Navigation Links
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
Date:5/20/2009

psule formulation, greater efficacy and reduced side effects.
  • Sales of Sinobiopharma's formulation of L-alanyl-L-glutamine for parenteral (intravenous) nutrition are projected to exceed 30,000 units in 2009.
  • The Company is in the process of submitting its application for approval of Rocuronium bromide, a next generation skeletal muscle relaxant that is also the first that can be stored at room temperature, to the Chinese Food and Drug Administration (SFDA).

  • "In the first quarter of 2009, we saw strong demand for our existing products," said Lequn Huang, Company President and CEO. "We expect that increased marketing efforts and expanded distribution will help boost additional growth for the rest of 2009, with projected improvements in both margins and profitability."

    About Sinobiopharma

    Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

        Contacts:
        Sinobiopharma, Inc.
        Investor Relations: 1-877-568-0188
    

    FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or resu
    '/>"/>

    SOURCE Sinobiopharma, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
    2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
    3. Sinobiopharma, Inc. Appoints New Director of Marketing
    4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
    5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
    6. Sinobiopharma Secures Rights to Seven Key Patents
    7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
    8. SemBioSys updates Apo AI development program
    9. Strategic Diagnostics Updates Roth Conference Presentation Time
    10. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
    11. SGX Pharmaceuticals Updates Date of Presentation at the BIO InvestorForum 2007
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
    (Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
    (Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
    (Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
    Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
    ... hurdle using Star-P, WALTHAM, Mass., Feb. ... Architecture Research Lab (NUCAR) and the National,Science ... Imaging,Systems (CenSSIS) are teaming with Massachusetts General ... detection technology that improves breast,cancer screening accuracy. ...
    ... (Nasdaq: NPSP ) announced today that Dr. Tony ... chief executive,officer and a director effective March 17, 2008 ... Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX). He will be succeeded by ... Nader, who will become president and chief,executive officer of ...
    ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged in ... aging, today announced,that results of a clinical study of ... Journal of Drugs in Dermatology., The study was ... over 12 weeks for improving the baseline clinical,signs and ...
    Cached Biology Technology:Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 2Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 3NPS Pharmaceuticals Announces Senior Management Changes 2NPS Pharmaceuticals Announces Senior Management Changes 3Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 2Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 3
    (Date:7/31/2015)... 31 juillet 2015 La 10e Conférence ... sera organisée par le BGI du 22 au ... en Chine. La conférence célèbre ... en 2006, l,ICG est devenue l,une des réunions ... des « omiques » et c,est aussi la plus dynamique, ...
    (Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
    (Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
    Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
    ... two-dozen countries have signed a consensus statement on the ... as the most serious and pervasive include overfishing, pollution, ... "This is first time the scientific ... express urgency over the environmental crisis facing the Pacific ...
    ... feeding frenzy that played out 73 million years ago ... of new dinosaur species in northwestern Alberta. University ... paleontology graduate student from Italy, made the discovery near ... Miyashita and Fanti came across a nesting site and ...
    ... Rare traits persist in a population because predators detect common ... access journal BMC Ecology found that birds will ... their behavior in response to alterations in the ratio of ... of Tennessee, worked with Kim Shook and Reuben Izally to ...
    Cached Biology News:Scientists urge world leaders to respond cooperatively to Pacific Ocean threats 2New dinosaur species possible in Northwestern Alberta 2
    The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
    ... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
    ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
    ...
    Biology Products: